Multifocal osteomyelitis caused by candida dubliniensis

Journal of Medical Microbiology

Volumn 58, Issue 3, 2009, Pages 386-390

  Wellinghausen, Nele ^a   Moericke, Angelika ^a   Bundschuh, Silke ^a   Friedrich, Wilhelm ^a   Schulz, Ansgar S ^a   Gatz, Susanne A ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; CEFTAZIDIME; CYCLOSPORIN; FLUCONAZOLE; FLUCYTOSINE; FLUDARABINE; ITRACONAZOLE; MELPHALAN; MEROPENEM; MYCOPHENOLIC ACID; THYMOCYTE ANTIBODY; VANCOMYCIN; VORICONAZOLE; YTTRIUM 90;

ADULT; ARTICLE; CANDIDA DUBLINIENSIS; CASE REPORT; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT VERSUS HOST REACTION; HEMOLYTIC ANEMIA; HUMAN; HUMAN TISSUE; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYELOABLATIVE CONDITIONING; NUCLEOTIDE SEQUENCE; OSTEOMYELITIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RADIOIMMUNOTHERAPY; SKIN BIOPSY;

ANEMIA, HEMOLYTIC, CONGENITAL; ANTIBODIES, FUNGAL; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; COMMUNICABLE DISEASES, EMERGING; DERMATOMYCOSES; ELECTROPHORESIS, GEL, PULSED-FIELD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; MALE; OSTEOMYELITIS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RADIOIMMUNOTHERAPY; SKIN; TIBIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 61449091353     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.003970-0     Document Type: Article

References (17)

1. Dodds Ashley, E. S., Lewis, R., Lewis, J. S., Martin, C. & Andes, C. (2006). Pharmacology of systemic antifungal agents. Clin Infect Dis 43, S28-S39.
2. Brandt, M. E., Harrison, L. H., Pass, M., Sofair, A. N., Huie, S., Li, R. K., Morrison, C. J., Warnock, D. W. & Hajjeh, R. A. (2000). Candida dubliniensis fungemia: the first four cases in North America. Emerg Infect Dis 6, 46-49.
3. Carr, M. J., Clarke, S., O'Connell, F., Sullivan, D. J., Coleman, D. C. & O'Connell, B. (2005). First reported case of endocarditis caused by Candida dubliniensis. J Clin Microbiol 43, 3023-3026.
4. Chan-Tack, K. M. (2005). Fatal Candida dubliniensis septicemia in a patient with AIDS. Clin Infect Dis 40, 1209-1210.
5. Eraso, E., Sahand, I. H., Villar-Vidal, M., Marcos, C., Dolores, M. M., Madariaga, L., Ponton, J. & Quindos, G. (2006). Usefulness of Candida ID2 agar for the presumptive identification of Candida dubliniensis. Med Mycol 44, 611-615.
6. Gee, S. F., Joly, S., Soll, D. R., Meis, J. F., Verweij, P. E., Polacheck, I., Sullivan, D. J. & Coleman, D. C. (2002). Identification of four distinct genotypes of Candida dubliniensis and detection of microevolution in vitro and in vivo. J Clin Microbiol 40, 556-574.
7. Jabra-Rizk, M. A., Johnson, J. K., Forrest, G., Mankes, K., Meiller, T. F. & Venezia, R. A. (2005). Prevalence of Candida dubliniensis fungemia at a large teaching hospital. Clin Infect Dis 41, 1064-1067.
8. Joly, S., Pujol, C. & Soll, D. R. (2002). Microevolutionary changes and chromosomal translocations are more frequent at RPS loci in Candida dubliniensis than in Candida albicans. Infect Genet Evol 2, 19-37.
9. Meis, J. F., Ruhnke, M., De Pauw, B. E., Odds, F. C., Siegert, W. & Verweij, P. E. (1999). Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis 5, 150-153.
10. Moran, G. P., Sullivan, D. J., Henman, M. C., McCreary, C. E., Harrington, B. J., Shanley, D. B. & Coleman, D. C. (1997). Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother 41, 617-623.
11. Nunn, M. A., Schaefer, S. M., Petrou, M. A. & Brown, J. R. (2007). Environmental source of Candida dubliniensis. Emerg Infect Dis 13, 747-750.
12. Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J. & Edwards, J. E. (2004). Guidelines for treatment of candidiasis. Clin Infect Dis 38, 161-189.
13. Salgado-Parreno, F. J., Alcoba-Florez, J., Arias, A., Moragues, M. D., Quindos, G., Ponton, J. & Arevalo, M. P. (2006). In vitro activities of voriconazole and five licensed antifungal agents against Candida dubliniensis: comparison of CLSI M27-A2, Sensititre YeastOne, disk diffusion, and Etest methods. Microb Drug Resist 12, 246-251.
14. Sebti, A., Kiehn, T. E., Perlin, D., Chaturvedi, V., Wong, M., Doney, A., Park, S. & Sepkowitz, K. A. (2001). Candida dubliniensis at a cancer center. Clin Infect Dis 32, 1034-1038.
15. Sullivan, D. J., Westerneng, T. J., Haynes, K. A., Bennett, D. E. & Coleman, D. C. (1995). Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 141, 1507-1521.
16. Sullivan, D. J., Moran, G. P., Pinjon, E., Al Mosaid, A., Stokes, C., Vaughan, C. & Coleman, D. C. (2004). Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS Yeast Res 4, 369-376.
17. Sullivan, D. J., Moran, G. P. & Coleman, D. C. (2005). Candida dubliniensis: ten years on. FEMS Microbiol Lett 253, 9-17.